Eragny-sur-Oise (France), April 15, 2015 – SAFE ORTHOPAEDICS (FR0012452746 – SAFOR / PEA PME eligible), a company developing and marketing an innovative range of sterile implants with associated disposable surgical instruments for spine surgery, announces its 2014 annual results and Q1 2015 revenue.
“Following two years essentially devoted to the industrialization and approval of our innovative single-use spine surgery solutions, 2014 was marked by Safe Orthopaedics’ international development. The investments thus made over the year enabled us to address 12 new countries and to increase our sales force in Europe and the United States where we have recruited 3 more sales managers since our IPO”, comments Yves Vignancour, CEO of Safe Orthopaedics. “These major breakthroughs in 2014 enabled us to enter 2015 with confidence and to record solid revenue growth of +56% in the first quarter of the year, including growth of +137% in the United States. We are reaffirming our 2015 objective; the number of spinal surgeries using our products this year should be more than double the 2014 figure.”
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the company’s CE-marked and FDA-approved SteriSpineTM kits are already being marketed in 12 countries, in Europe and the United States. They are being rapidly adopted by surgeons throughout the world, with nearly 1,500 procedures performed during the past 12 months. The company is based at Eragny-sur-Oise (France), and has 32 employees and a US subsidiary.
For more information, visit: www.SafeOrtho.com
CONTACTS
Yves Vignancour
CEO
Elvire Huisse
CFO
Tel. : +33 (0)1 34 21 50 00
[email protected]
NewCap
Julien Perez/Valentine Brouchot
Investor Relations
Nicolas Merigeau
Press Relations
Tel. : +33 (0)1 44 71 94 94
[email protected]